A senior member of the founding Takeda family spoke out against the Shire deal for the first time, calling it a betrayal of company culture.
Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.
The deal relieves Novartis of a troubled franchise while boosting buyer Aurobindo to the second-largest generics player by prescriptions in the U.S.
China, which has been waving through cancer drugs made by multinational pharmas, can now count a homegrown one among its approvals.
CDMO Olon is continuing its expansion binge with a deal to buy an API plant in India that supplies ingredients to Novartis.
In probably a new drug scandal from China, self-proclaimed employees alleged that a Fosun unit faked production and testing records.
It was a U.S. drugmaker that first alerted the FDA that a valsartan API from a Chinese ingredient maker contained a a dangerous impurity.
Ascletis' stock price slips 44% in a month on HKEX; Zai Lab cans a dermatitis drug licensed from GSK; WuXi names CFO a co-CEO; and more.
China has withheld shipments of the H7N9 strain to the U.S. for research, according to The New York Times.
The Nasdaq-listed plasma specialist is raising $590 million via share issuance to fund business expansion plans and strategic acquisitions.